In BC, including TNBC, PIK3CA mutations are very common; consequently, PI3Kα-specific inhibitors—a class of selective oral inhibitors targeting the PI3K catalytic subunit P110α class I—have been extensively studied. This evidence concerns the gene PIK3CA and breast cancer.